Lactospore Bacillus Coagulans Mtcc5856
Also known as: Bacillus coagulans MTCC 5856, Weizmannia coagulans MTCC 5856, Lactospore, Bacillus coagulans, Probiotic spores
Overview
Bacillus coagulans MTCC 5856, sometimes referred to as Weizmannia coagulans, is a spore-forming probiotic bacterium used as a dietary supplement to support gut health. Its spore-forming ability allows it to survive the harsh conditions of the gastrointestinal tract, ensuring effective delivery to the intestines. It is primarily used to manage gastrointestinal disorders such as irritable bowel syndrome (IBS) and diarrhea. Research indicates that this strain modulates the gut microbiota, improves epithelial barrier function, and alters host immune activity. Available evidence is derived from randomized controlled trials and systematic reviews, supporting its efficacy and safety. It is known for its stability and resilience, making it a reliable option for probiotic supplementation. It is available in various forms, including capsules and tablets, and is sourced through controlled fermentation processes.
Benefits
Bacillus coagulans MTCC 5856 has demonstrated several evidence-based benefits, particularly for gastrointestinal health. Studies have shown significant improvements in IBS symptoms, including bloating, abdominal pain, diarrhea, and stool frequency. A randomized controlled trial found a significant reduction in these symptoms (p < 0.01) compared to placebo. Furthermore, it has been shown to improve depression symptoms in IBS patients, as measured by the Hamilton Rating Scale for Depression (HAM-D) (p = 0.01). In children, this probiotic has been shown to reduce the duration of diarrhea by approximately 17 hours (p = 0.012). It also supports overall gut health by modulating the microbiota composition, host immunity, and metabolism. These benefits have been observed within 90 days of supplementation for IBS symptoms and within a few days for diarrhea duration in children.
How it works
Bacillus coagulans MTCC 5856 exerts its beneficial effects through several mechanisms. Primarily, it modulates the composition of the gut microbiota, promoting a more balanced and healthy microbial environment. It also improves the barrier function of the intestinal epithelium, reducing gut permeability and preventing the translocation of harmful substances. Additionally, it alters the immune activity of the host, modulating immune responses to reduce inflammation and improve overall gut health. Its spore-forming nature enhances its survival through the stomach and small intestine, ensuring effective colonization in the gut. By suppressing the growth of pathogenic bacteria and enhancing epithelial barrier function, it contributes to improved digestive health and immune function.
Side effects
Bacillus coagulans MTCC 5856 is generally considered safe for human consumption, with studies reporting no significant adverse events. Common, uncommon, and rare side effects have not been reported in clinical trials. No significant drug interactions have been documented. However, certain populations were excluded from studies, including patients on antibiotics, those using complementary and alternative medicines for IBS, pregnant or lactating women, and those with untreated lactose intolerance or regular probiotic use. While generally safe for children and adults, pregnant or lactating women should consult healthcare providers before use. All safety parameters have remained within normal clinical ranges in studies, indicating a favorable safety profile. It is important to adhere to recommended dosages to minimize any potential risks.
Dosage
The minimum effective dose of Bacillus coagulans MTCC 5856 is typically around 2 billion CFU (colony-forming units) per day. The optimal dosage range is between 2 billion to 10 billion CFU per day, depending on the specific condition being treated. Doses up to 10 billion CFU per day have been used safely in clinical trials. It can be taken at any time of day, but it is often recommended to take it with meals to enhance survival through the stomach. It is available in capsule or tablet form, and its spore-forming nature makes it stable at room temperature and resistant to stomach acid. No specific cofactors are required for its efficacy. Adhering to these guidelines ensures optimal benefits while minimizing potential risks.
FAQs
Is Bacillus coagulans MTCC 5856 safe?
Yes, it is generally considered safe with no significant adverse events reported in clinical trials. However, pregnant or lactating women should consult healthcare providers before use.
When should I take Bacillus coagulans MTCC 5856?
It can be taken at any time, preferably with meals to enhance survival through the stomach. Consistency in timing can help optimize its effects.
What results can I expect from taking Bacillus coagulans MTCC 5856?
You may experience improvement in IBS symptoms, reduction in diarrhea duration, and potential improvement in depression symptoms if you have IBS. Individual results may vary.
Is Bacillus coagulans MTCC 5856 a live culture?
It is not a live culture in the traditional sense but rather a spore-forming bacterium, which enhances its stability and efficacy, allowing it to survive stomach acid.
Research Sources
- https://foodandnutritionresearch.net/index.php/fnr/article/view/1218 – This randomized controlled trial examined the effects of Bacillus coagulans MTCC 5856 on patients with major depressive disorder and IBS. The study found significant improvements in both depression and IBS symptoms after 90 days. The high-quality RCT design and significant clinical outcomes support the efficacy of this probiotic strain.
- https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1310462/full – This randomized, double-blind, placebo-controlled trial investigated the effects of Weizmannia (Bacillus) coagulans LMG S-31876 in patients with diarrhea-predominant IBS. The study reported a significant improvement in IBS symptoms and quality of life after 8 weeks. The RCT design and proper control groups enhance the reliability of these findings.
- https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2023.1338126/full – This randomized, double-blind, placebo-controlled trial assessed the efficacy of Probiotic Weizmannia coagulans MTCC 5856 in children with diarrhea. The study found that the probiotic reduced the duration of diarrhea by 17.22 hours. The high-quality RCT design and significant clinical outcomes support the use of this probiotic in pediatric diarrhea management.
- https://pubmed.ncbi.nlm.nih.gov/26922379/ – This study investigates the effects of Bacillus coagulans on irritable bowel syndrome (IBS) symptoms. The research indicates a significant reduction in IBS-related discomfort and improved bowel function among participants. The findings suggest that Bacillus coagulans may be a beneficial probiotic for managing IBS symptoms.
- https://www.springermedizin.de/bacillus-coagulans-mtcc-5856-supplementation-in-the-management-o/25658796 – This article discusses the use of Bacillus coagulans MTCC 5856 supplementation in the management of various gastrointestinal conditions. It highlights the probiotic's ability to improve gut health and alleviate symptoms associated with digestive disorders. The information suggests that Bacillus coagulans MTCC 5856 is a valuable supplement for promoting a healthy gut microbiome.